Comparative Pharmacology
Head-to-head clinical analysis: EPIPEN versus EPIPEN E Z PEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EPIPEN versus EPIPEN E Z PEN.
EPIPEN vs EPIPEN E Z PEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonselective alpha-1, alpha-2, beta-1, beta-2, beta-3 adrenergic receptor agonist; causes vasoconstriction (alpha-1), bronchodilation (beta-2), and increased cardiac contractility and heart rate (beta-1).
Epinephrine is a direct-acting sympathomimetic amine that acts on alpha- and beta-adrenergic receptors. Alpha-adrenergic stimulation increases peripheral vascular resistance, reversing hypotension and improving coronary perfusion. Beta-adrenergic stimulation causes bronchodilation, positive inotropy, and chronotropy.
0.3 mg intramuscularly (lateral thigh) every 5-15 minutes as needed for anaphylaxis.
0.3 mg intramuscularly every 5-15 minutes as needed for anaphylaxis. Administer into anterolateral thigh.
None Documented
None Documented
2-3 minutes (IV); clinical context: ultra-short half-life necessitates repeated doses or continuous infusion for sustained effect
The terminal elimination half-life of epinephrine is approximately 2-3 minutes when administered intravenously. The short half-life necessitates repeated doses or continuous infusion for sustained effect.
Renal (90% as metabolites, 10% unchanged); biliary/fecal (<5%)
Epinephrine is rapidly metabolized in the liver and other tissues by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO). Approximately 80-90% of an intravenous dose is excreted in the urine as inactive metabolites (metanephrine, vanillylmandelic acid, 3,4-dihydroxymandelic acid) with less than 5% excreted unchanged.
Category C
Category C
Adrenergic Agonist
Adrenergic Agonist